Circulating Concentrations of Vitamin B6 and Kidney Cancer Prognosis: A Prospective Case-Cohort Study.
Prospective cohort studies have found that prediagnostic circulating vitamin B6 is inversely associated with both risk of kidney cancer and kidney cancer prognosis. We investigated whether circulating concentrations of vitamin B6 at kidney cancer diagnosis are associated with risk of death using a case-cohort study of 630 renal cell carcinoma (RCC) patients. Blood was collected at the time of diagnosis, and vitamin B6 concentrations were quantified using LC-MS/MS. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox regression models. After adjusting for stage, age, and sex, the hazard was 3 times lower among those in the highest compared to the lowest fourth of B6 concentration (HR4vs1 0.33, 95% CI [0.18, 0.60]). This inverse association was solely driven by death from RCC (HR4vs1 0.22, 95% CI [0.11, 0.46]), and not death from other causes (HR4vs1 0.89, 95% CI [0.35, 2.28], p-interaction = 0.008). These results suggest that circulating vitamin B6 could provide additional prognostic information for kidney cancer patients beyond that afforded by tumour stage.
International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69372 Lyon cedex 08, France.
David C
DC
Muller
International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69372 Lyon cedex 08, France.
Mattias
M
Johansson
Russian N.N. Blokhin Cancer Research Centre, Kashirskoye Shosse 24, 115478 Moscow, Russian Federation.
David
D
Zaridze
Russian N.N. Blokhin Cancer Research Centre, Kashirskoye Shosse 24, 115478 Moscow, Russian Federation.
Anush
A
Moukeria
Department of Preventive Medicine, Faculty of Medicine, Palacky University, Hnevotinska 3, CZ 775 15 Olomouc, Czech Republic.
Vladimir
V
Janout
Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University Prague, Studnickova 7, CZ 128 00 Prague 2, Czech Republic.
Ivana
I
Holcatova
Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, CZ 656 53, Brno, Czech Republic.
Marie
M
Navratilova
National Institute of Public Health, Str. Dr. Leonte Anastasievici Nr.1-3, Sector 5, 050463 Bucharest, Romania.
Dana
D
Mates
Bevital AS, co/Helse Bergen, Laboratoriebygget 9 etg., NO-5021 Bergen, Norway.
Øivind
Ø
Midttun
Department of Clinical Science, University of Bergen, New Laboratory Building, 9th floor, NO-5021 Bergen, Norway; Laboratory of Clinical Biochemistry, Haukeland University Hospital, P.O. Box 1400, 5021 Bergen, Norway.
Per Magne
PM
Ueland
International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69372 Lyon cedex 08, France.
Paul
P
Brennan
International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69372 Lyon cedex 08, France.
Ghislaine
G
Scelo
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D025101:Vitamin B 6 / Q000097:blood*
D025101:Vitamin B 6